Rosuvastatin for Reduction of Myocardial Damage and Systemic Inflammation During Coronary Angioplasty

Launched by G. D'ANNUNZIO UNIVERSITY · Jul 30, 2014

Keywords

ClinConnect Summary

Myocardial necrosis, assessed by creatine kinase-MB (CK-MB) elevation, is relatively frequent after percutaneous coronary intervention (PCI), occurring in up to 40% of cases. Although most patients remain asymptomatic and with no changes in cardiac function, even a mild release of CK-MB is associated with higher mortality during the follow-up. A number of treatment strategies have been proposed to limit myocardial damage during PCI, but procedural ischemic myocardial injury remains the most frequent complication after coronary angioplasty.

Several randomized studies have demonstrated the b...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • - suspected CAD for which an indication to PCI is given: both patients with stable CAD, and stable post-acute coronary syndromes (ACS), both with ST-segment elevation (STEMI) and without ST-segment elevation (NSTE-ACS) patients, provided that markers of myocardial necrosis (CK-MB, troponins) are stabilized (i.e., with variations \<20% in two consecutive measurements obtained at ≥6 h time distance before PCI, according to the universal definition of peri-procedural myocardial infarction).
• Exclusion Criteria:
• • any previously known increase in liver enzymes (AST, ALT) ascribed to liver dysfunction at baseline;
• • history of liver toxicity or myopathy on previous treatment with statins;
• • left ventricular ejection fraction \<30%;
• • renal insufficiency, with creatinine \>2 mg/dL at baseline;
• • ongoing treatment with high-dose statins (atorvastatin 80 mg/d or rosuvastatin 40 mg/d);
• • pregnant or lactating women.